Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of P...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2009
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23457
- Acceso en línea:
- https://doi.org/10.1016/j.vaccine.2009.10.034
https://repository.urosario.edu.co/handle/10336/23457
- Palabra clave:
- Chloroquine
Gamma interferon
Interleukin 10
Interleukin 2
Interleukin 4
Interleukin 5
Malaria vaccine
Primaquine
Recombinant plasmodium vivax 34 antigen
Recombinant protein
Tumor necrosis factor alpha
Unclassified drug
Animal experiment
Article
Blood sampling
Cytokine release
Drug antigenicity
Human
Humoral immunity
Immunogenicity
Lymphocyte proliferation
Molecular biology
Monkey
Nonhuman
Nucleotide sequence
Peripheral blood mononuclear cell
Plasmodium vivax
Plasmodium vivax malaria
Priority journal
Protein blood level
Rabbit
Adult
Aged
Animals
Cytokines
Haplorhini
Humans
Malaria vaccines
Middle aged
Plasmodium vivax
Protozoan proteins
Rabbits
Pf34 homologue
Plasmodium vivax
Vaccine candidate
indirect
polyacrylamide gel
western
Blotting
Electrophoresis
Fluorescent antibody technique
- Rights
- License
- Abierto (Texto Completo)
Summary: | This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria. © 2009 Elsevier Ltd. All rights reserved. |
---|